Abstract：This article summarizes and analyzes the clinical features and gene mutation characteristics of children with noncompaction of the ventricular myocardium (NVM). For the 6 children with NVM (4 boys and 2 girls), the age of onset ranged from 3 months to 12 years. Of the 6 children, 5 had arrhythmia, 3 had cardiac insufficiency, 1 had poor mental state, and 1 had chest distress and sighing. NVM-related gene mutations were detected in 4 children, among whom 2 had MYH7 gene mutation, 1 had PRDM16 gene mutation, and 1 had mutations in the ACTN2 and TNNT2 genes. Four children had improvement in cardiac function. The two children with no significant improvement in cardiac function had a younger age of onset, a greater reduction in systolic function on echocardiography, and greater increases in myocardial enzyme and N-terminal pro-brain natriuretic peptide. It is concluded that for children with the initial symptoms of chest distress, sighing, arrhythmia, enlarged heart shadow, and increased myocardial enzyme, echocardiography and cardiac magnetic resonance are recommended for the diagnosis of NVM. NVM can have various genetic mutations.
ZHANG Feng-Hua,AN Jin-Dou,FENG Song et al. Clinical manifestations and gene mutation analysis of children with noncompaction of the ventricular myocardium: an analysis of 6 cases[J]. CJCP, 2021, 23(1): 84-90.
Jefferies JL, Wilkinson JD, Sleeper LA, et al. Cardiomyopathy phenotypes and outcomes for children with left ventricular myocardial noncompaction:results from the pediatric cardiomyopathy registry[J]. J Card Fail, 2015, 21(11):877-884.
[3]
Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention[J]. Circulation, 2006, 113(14):1807-1816.
[4]
Silvera VM, Gordon LB, Orbach DB, et al. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome[J]. AJNR Am J Neuroradiol, 2013, 34(5):1091-1097.
Jenni R, Oechslin E, Schneider J, et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction:a step towards classification as a distinct cardiomyopathy[J]. Heart, 2001, 86(6):666-671.
[7]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J].Genet Med, 2015, 17(5):405-424.
Liu Y, Chen H, Shou W. Potential common pathogenic pathways for the left ventricular noncompaction cardiomyopathy (LVNC)[J]. Pediatr Cardiol, 2018, 39(6):1099-1106.
[10]
Engberding R, Bender F. Identification of a rare congenital anomaly of the myocardium by two-dimensional echocardiography:persistence of isolated myocardial sinusoids[J]. Am J Cardiol, 1984, 53(11):1733-1734.
[11]
Lee TM, Hsu DT, Kantor P, et al. Pediatric cardiomyopathies[J]. Circ Res, 2017, 121(7):855-873.
[12]
Long PA, Evans JM, Olson TM. Diagnostic yield of whole exome sequencing in pediatric dilated cardiomyopathy[J]. J Cardiovasc Dev Dis, 2017, 4(3):11.
Klaassen S, Probst S, Oechslin E, et al. Mutations in sarcomere protein genes in left ventricular noncompaction[J]. Circulation, 2008, 117(22):2893-2901.
[15]
Debold EP, Schmitt JP, Patlak JB, et al. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse α-cardiac myosin in the laser trap assay[J]. Am J Physiol Heart Circ Physiol, 2007, 293(1):H284-H291.
[16]
Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel β cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy[J]. J Clin Invest, 1994, 93(1):280-285.
Murphy AC, Young PW. The actinin family of actin crosslinking proteins-a genetic perspective[J]. Cell Biosci, 2015, 5:49.
[19]
Finsterer J, Stöllberger C, Towbin JA. Left ventricular noncompaction cardiomyopathy:cardiac, neuromuscular, and genetic factors[J]. Nat Rev Cardiol, 2017, 14(4):224-237.
[20]
van Waning JI, Caliskan K, Hoedemaekers YM, et al. Genetics, clinical features, and long-term outcome of noncompaction cardiomyopathy[J]. J Am Coll Cardiol, 2018, 71(7):711-722.
Kayvanpour E, Sedaghat-Hamedani F, Gi WT, et al. Clinical and genetic insights into non-compaction:a meta-analysis and systematic review on 7598 individuals[J]. Clin Res Cardiol, 2019, 108(11):1297-1308.
